The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?
- 30 April 2000
- journal article
- review article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 36, 4-10
- https://doi.org/10.1016/s0959-8049(99)00256-7
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Doxorubicin (A) followed by docetaxel (T) versus doxorubicin + docetaxel (AT) in the adjuvant treatment of breast cancer (BC)European Journal of Cancer, 1998
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998
- More on dose-intensity of anthracyclines in breast cancerAnnals of Oncology, 1998
- The bigger the better? … or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancerAnnals of Oncology, 1997
- Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.Journal of Clinical Oncology, 1997
- 372 Neo-adjuvant chemotherapy in locally advanced beast cancer (LABC): FEC (5FU, epirubicin, cyclophosphamide) vs high dose intensity EC+G-CSF (Filgrastim). An EORTC—NCIC—SAKK study. Preliminary results of dose intensity (DI)European Journal of Cancer, 1995
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaThe New England Journal of Medicine, 1994
- Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer.Journal of Clinical Oncology, 1989
- More is better.Journal of Clinical Oncology, 1988